Search

Your search keyword '"Cordoro, Kelly M."' showing total 387 results
Start Over Author "Cordoro, Kelly M."
387 results on '"Cordoro, Kelly M."'

59. Acral Changes in pediatric patients during COVID 19 pandemic: Registry report from the COVID 19 response task force of the society of pediatric dermatology (SPD) and pediatric dermatology research alliance (PeDRA)

Author

Castelo‐Soccio, Leslie, primary, Lara‐Corrales, Irene, additional, Paller, Amy S., additional, Bean, Eric, additional, Rangu, Sneha, additional, Oboite, Michelle, additional, Flohr, Carsten, additional, Ahmad, Regina‐Celeste, additional, Calberg, Valerie, additional, Gilliam, Amy, additional, Pope, Elena, additional, Reynolds, Sean, additional, Sibbald, Cathryn, additional, Shin, Helen T., additional, Berger, Emily, additional, Schaffer, Julie, additional, Siegel, Michael P., additional, and Cordoro, Kelly M., additional

Published
2021
Full Text
View/download PDF

60. A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents

Author

Bronckers, Inge M. G. J. Paller, Amy S. West, Dennis P. and Lara-Corrales, Irene Tollefson, Megha M. Tom, Wynnis L. and Hogeling, Marcia Belazarian, Leah Zachariae, Claus Mahe, Emmanuel Siegfried, Elaine Blume-Peytavi, Ulrike Szalai, Zsuzsanna Vleugels, Ruth Ann Holland, Kristen Murphy, Ruth and Puig, Lluis Cordoro, Kelly M. Lambert, Jo Alexopoulos, Alex Mrowietz, Ulrich Kievit, Wietske Seyger, Marieke M. B. and Psoriasis Investigator Grp Pediat Dermatology Res Alliance and European Working Grp Pediat

Abstract

This cohort study compares the use of methotrexate vs biologic agents in children with moderate to severe psoriasis. Question What is the association between use of methotrexate vs biologics and psoriasis severity and drug survival (rate and duration of adherence to a specific drug regimen) in pediatric patients with moderate to severe psoriasis? Findings In this cohort study including 234 pediatric patients with moderate to severe psoriasis, those receiving biologics were more likely than those treated with methotrexate to achieve a Physician Global Assessment status of clear/almost clear and 75% or more improvement of the Psoriasis Area and Severity Index rating at 6 months. In addition, biologics were associated with better drug survival rates at 1, 3, and 5 years, with comparable discontinuation rates owing to lack of response. Meaning In pediatric patients with psoriasis, treatment with biologics may be associated with a significantly greater reduction in psoriasis severity than methotrexate; nevertheless, with 35.6% of the patients achieving clear/almost clear and 40.0% reaching 75% or more improvement on the Psoriasis Area and Severity Index, methotrexate remains an effective treatment for pediatric psoriasis. Importance Few studies have compared the use of methotrexate and biologics, the most commonly used systemic medications for treatment of moderate to severe psoriasis in children. Objective To assess the real-world, 6-month reduction in psoriasis severity and long-term drug survival (rate and duration of adherence to a specific drug) of methotrexate vs biologics in plaque psoriasis in children. Design, Setting, and Participants A retrospective medical records review was conducted at 20 European and North American centers. Treatment response was based on site-reported Psoriasis Area and Severity Index (PASI) and/or Physician Global Assessment (PGA) scores at baseline and within the first 6 months of treatment. Participants included all 234 consecutively seen children with moderate to severe psoriasis who received at least 3 months of methotrexate or biologics from December 1, 1990, to September 16, 2014, with sufficient data for analysis. Data analysis was performed from December 14, 2015, to September 1, 2016. Main Outcomes and Measures PASI, with a range from 0 to 72 (highest score indicating severe psoriasis), and/or PGA, with a scale of 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), and 5 (very severe). Results Of 234 pediatric patients (103 boys [44.0%]; 131 girls [56.0%]) treated with methotrexate and/or biologics, 163 patients (69.7%) exclusively received methotrexate, 47 patients (20.1%) exclusively received biologics, and 24 children (10.2%) received methotrexate and biologics sequentially. Of the latter cohort, 23 children were treated initially with methotrexate. Mean (SD) age at initiation was 11.6 (3.7) years for methotrexate and 13.3 (2.9) years for biologics (73.2% for etanercept) (P = .002). Among patients evaluated by a scoring method at 6-month follow-up, 75% or greater improvement in PASI (PASI75) was achieved in 12 of 30 patients (40.0%) receiving methotrexate and 20 of 28 patients (71.4%) receiving biologics, and PGA was clear/almost clear (PGA 0/1) in 41 of 115 patients (35.6%) receiving methotrexate and 18 of 37 patients (48.6%) receiving biologics. Achieving PASI75 and/or PGA 0/1 between baseline and 6 months was more likely with biologics than methotrexate (PASI75: odds ratio [OR], 4.56; 95% CI, 2.02-10.27; P < .001; and PGA 0/1: OR, 2.00; 95% CI, 0.98-4.00; P = .06). Decreased mean PASI and PGA scores were associated with biologics more than with methotrexate (PASI effect, -3.13; 95% CI, -4.33 to -1.94; P < .001; and PGA effect, -0.31; 95% CI, -0.56 to -0.06; P = .02). After 1, 3, and 5 years of use, overall drug survival rates for methotrexate were 77.5%, 50.3%, and 35.9%, and for biologics, the rates were 83.4%, 64.3%, and 57.1%, respectively. Biologics were associated with a better confounder-corrected drug survival than methotrexate (hazard ratio [HR], 2.23; 95% CI, 1.21-4.10; P = .01). Discontinuation owing to lack of response was comparable (HR, 1.64; 95% CI, 0.80-3.36; P = .18). Conclusions and Relevance Methotrexate and biologics appear to be associated with improvement in pediatric psoriasis, although biologics seem to be associated with greater reduction in psoriasis severity scores and higher drug survival rates than methotrexate in the real-world setting. Additional studies directly comparing these medications should be performed for confirmation.

Published
2020

61. A Comparison of Psoriasis Severity in Pediatric Patients Treated with Methotrexate vs Biologic Agents

Author

Bronckers, Inge M.G.J., Paller, Amy S., West, Dennis P., Lara-Corrales, Irene, Tollefson, Megha M., Tom, Wynnis L., Hogeling, Marcia, Belazarian, Leah, Zachariae, Claus, Mahé, Emmanuel, Siegfried, Elaine, Blume-Peytavi, Ulrike, Szalai, Zsuzsanna, Vleugels, Ruth Ann, Holland, Kristen, Murphy, Ruth, Puig, Lluís, Cordoro, Kelly M., Lambert, Jo, Alexopoulos, Alex, Mrowietz, Ulrich, Kievit, Wietske, Seyger, Marieke M.B., Bronckers, Inge M.G.J., Paller, Amy S., West, Dennis P., Lara-Corrales, Irene, Tollefson, Megha M., Tom, Wynnis L., Hogeling, Marcia, Belazarian, Leah, Zachariae, Claus, Mahé, Emmanuel, Siegfried, Elaine, Blume-Peytavi, Ulrike, Szalai, Zsuzsanna, Vleugels, Ruth Ann, Holland, Kristen, Murphy, Ruth, Puig, Lluís, Cordoro, Kelly M., Lambert, Jo, Alexopoulos, Alex, Mrowietz, Ulrich, Kievit, Wietske, and Seyger, Marieke M.B.

Abstract

Importance: Few studies have compared the use of methotrexate and biologics, the most commonly used systemic medications for treatment of moderate to severe psoriasis in children. Objective: To assess the real-world, 6-month reduction in psoriasis severity and long-term drug survival (rate and duration of adherence to a specific drug) of methotrexate vs biologics in plaque psoriasis in children. Design, Setting, and Participants: A retrospective medical records review was conducted at 20 European and North American centers. Treatment response was based on site-reported Psoriasis Area and Severity Index (PASI) and/or Physician Global Assessment (PGA) scores at baseline and within the first 6 months of treatment. Participants included all 234 consecutively seen children with moderate to severe psoriasis who received at least 3 months of methotrexate or biologics from December 1, 1990, to September 16, 2014, with sufficient data for analysis. Data analysis was performed from December 14, 2015, to September 1, 2016. Main Outcomes and Measures: PASI, with a range from 0 to 72 (highest score indicating severe psoriasis), and/or PGA, with a scale of 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), and 5 (very severe). Results: Of 234 pediatric patients (103 boys [44.0%]; 131 girls [56.0%]) treated with methotrexate and/or biologics, 163 patients (69.7%) exclusively received methotrexate, 47 patients (20.1%) exclusively received biologics, and 24 children (10.2%) received methotrexate and biologics sequentially. Of the latter cohort, 23 children were treated initially with methotrexate. Mean (SD) age at initiation was 11.6 (3.7) years for methotrexate and 13.3 (2.9) years for biologics (73.2% for etanercept) (P =.002). Among patients evaluated by a scoring method at 6-month follow-up, 75% or greater improvement in PASI (PASI75) was achieved in 12 of 30 patients (40.0%) receiving methotrexate and 20 of 28 patients (71.4%) receiving biologics, and PGA was clear

Published
2020

70. International collaboration and rapid harmonization across dermatologic COVID-19 registries

Author

Freeman, Esther E., primary, McMahon, Devon E., additional, Hruza, George J., additional, Irvine, Alan D., additional, Spuls, Phyllis I., additional, Smith, Catherine H., additional, Mahil, Satveer K., additional, Castelo-Soccio, Leslie, additional, Cordoro, Kelly M., additional, Lara-Corrales, Irene, additional, Naik, Haley B., additional, Alhusayen, Raed, additional, Ingram, John R., additional, Feldman, Steven R., additional, Balogh, Esther A., additional, Kappelman, Michael D., additional, Wall, Dmitri, additional, Meah, Nekma, additional, Sinclair, Rodney, additional, Beylot-Barry, Marie, additional, Fitzgerald, Matthew, additional, French, Lars E., additional, Lim, Henry W., additional, Griffiths, Christopher E.M., additional, and Flohr, Carsten, additional

Published
2020
Full Text
View/download PDF

71. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies

Author

Menter, Alan, primary, Gelfand, Joel M., additional, Connor, Cody, additional, Armstrong, April W., additional, Cordoro, Kelly M., additional, Davis, Dawn M.R., additional, Elewski, Boni E., additional, Gordon, Kenneth B., additional, Gottlieb, Alice B., additional, Kaplan, Daniel H., additional, Kavanaugh, Arthur, additional, Kiselica, Matthew, additional, Kivelevitch, Dario, additional, Korman, Neil J., additional, Kroshinsky, Daniela, additional, Lebwohl, Mark, additional, Leonardi, Craig L., additional, Lichten, Jason, additional, Lim, Henry W., additional, Mehta, Nehal N., additional, Paller, Amy S., additional, Parra, Sylvia L., additional, Pathy, Arun L., additional, Prater, Elizabeth Farley, additional, Rahimi, Robert S., additional, Rupani, Reena N., additional, Siegel, Michael, additional, Stoff, Benjamin, additional, Strober, Bruce E., additional, Tapper, Elliot B., additional, Wong, Emily B., additional, Wu, Jashin J., additional, Hariharan, Vidhya, additional, and Elmets, Craig A., additional

Published
2020
Full Text
View/download PDF

73. Systemic immunosuppressive therapy for inflammatory skin diseases in children: Expert consensus‐based guidance for clinical decision‐making during the COVID‐19 pandemic

Author

Reynolds, Sean D., primary, Mathur, Anubhav N., additional, Chiu, Yvonne E., additional, Brandling‐Bennett, Heather A., additional, Pope, Elena, additional, Siegel, Michael P., additional, Holland, Kristen E., additional, Paller, Amy S., additional, Siegfried, Elaine C., additional, Tom, Wynnis L., additional, Lara‐Corrales, Irene, additional, Tollefson, Megha M., additional, Maguiness, Sheilagh, additional, Eichenfield, Lawrence F., additional, Sugarman, Jeffrey, additional, Frieden, Ilona J., additional, Oza, Vikash S., additional, Cipriano, Sarah D., additional, Huang, Jennifer T., additional, Shah, Sonal D., additional, Lauren, Christine T., additional, Castelo‐Soccio, Leslie, additional, McMahon, Patrick, additional, and Cordoro, Kelly M., additional

Published
2020
Full Text
View/download PDF

75. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients

Author

Menter, Alan, primary, Cordoro, Kelly M., additional, Davis, Dawn M.R., additional, Kroshinsky, Daniela, additional, Paller, Amy S., additional, Armstrong, April W., additional, Connor, Cody, additional, Elewski, Boni E., additional, Gelfand, Joel M., additional, Gordon, Kenneth B., additional, Gottlieb, Alice B., additional, Kaplan, Daniel H., additional, Kavanaugh, Arthur, additional, Kiselica, Matthew, additional, Kivelevitch, Dario, additional, Korman, Neil J., additional, Lebwohl, Mark, additional, Leonardi, Craig L., additional, Lichten, Jason, additional, Lim, Henry W., additional, Mehta, Nehal N., additional, Parra, Sylvia L., additional, Pathy, Arun L., additional, Farley Prater, Elizabeth A., additional, Rupani, Reena N., additional, Siegel, Michael, additional, Stoff, Benjamin, additional, Strober, Bruce E., additional, Wong, Emily B., additional, Wu, Jashin J., additional, Hariharan, Vidhya, additional, and Elmets, Craig A., additional

Published
2020
Full Text
View/download PDF

83. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy

Author

Elmets, Craig A., primary, Lim, Henry W., additional, Stoff, Benjamin, additional, Connor, Cody, additional, Cordoro, Kelly M., additional, Lebwohl, Mark, additional, Armstrong, April W., additional, Davis, Dawn M.R., additional, Elewski, Boni E., additional, Gelfand, Joel M., additional, Gordon, Kenneth B., additional, Gottlieb, Alice B., additional, Kaplan, Daniel H., additional, Kavanaugh, Arthur, additional, Kiselica, Matthew, additional, Kivelevitch, Dario, additional, Korman, Neil J., additional, Kroshinsky, Daniela, additional, Leonardi, Craig L., additional, Lichten, Jason, additional, Mehta, Nehal N., additional, Paller, Amy S., additional, Parra, Sylvia L., additional, Pathy, Arun L., additional, Farley Prater, Elizabeth A., additional, Rupani, Reena N., additional, Siegel, Michael, additional, Strober, Bruce E., additional, Wong, Emily B., additional, Wu, Jashin J., additional, Hariharan, Vidhya, additional, and Menter, Alan, additional

Published
2019
Full Text
View/download PDF

84. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

Author

Menter, Alan, primary, Strober, Bruce E., additional, Kaplan, Daniel H., additional, Kivelevitch, Dario, additional, Prater, Elizabeth Farley, additional, Stoff, Benjamin, additional, Armstrong, April W., additional, Connor, Cody, additional, Cordoro, Kelly M., additional, Davis, Dawn M.R., additional, Elewski, Boni E., additional, Gelfand, Joel M., additional, Gordon, Kenneth B., additional, Gottlieb, Alice B., additional, Kavanaugh, Arthur, additional, Kiselica, Matthew, additional, Korman, Neil J., additional, Kroshinsky, Daniela, additional, Lebwohl, Mark, additional, Leonardi, Craig L., additional, Lichten, Jason, additional, Lim, Henry W., additional, Mehta, Nehal N., additional, Paller, Amy S., additional, Parra, Sylvia L., additional, Pathy, Arun L., additional, Rupani, Reena N., additional, Siegel, Michael, additional, Wong, Emily B., additional, Wu, Jashin J., additional, Hariharan, Vidhya, additional, and Elmets, Craig A., additional

Published
2019
Full Text
View/download PDF

85. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities

Author

Elmets, Craig A., primary, Leonardi, Craig L., additional, Davis, Dawn M.R., additional, Gelfand, Joel M., additional, Lichten, Jason, additional, Mehta, Nehal N., additional, Armstrong, April W., additional, Connor, Cody, additional, Cordoro, Kelly M., additional, Elewski, Boni E., additional, Gordon, Kenneth B., additional, Gottlieb, Alice B., additional, Kaplan, Daniel H., additional, Kavanaugh, Arthur, additional, Kivelevitch, Dario, additional, Kiselica, Matthew, additional, Korman, Neil J., additional, Kroshinsky, Daniela, additional, Lebwohl, Mark, additional, Lim, Henry W., additional, Paller, Amy S., additional, Parra, Sylvia L., additional, Pathy, Arun L., additional, Prater, Elizabeth Farley, additional, Rupani, Reena, additional, Siegel, Michael, additional, Stoff, Benjamin, additional, Strober, Bruce E., additional, Wong, Emily B., additional, Wu, Jashin J., additional, Hariharan, Vidhya, additional, and Menter, Alan, additional

Published
2019
Full Text
View/download PDF

87. CARD14-associated papulosquamous eruption : A spectrum including features of psoriasis and pityriasis rubra pilaris

Author

Craiglow, Brittany G., Boyden, Lynn M., Hu, Ronghua, Virtanen, Marie, Su, John, Rodriguez, Gabriela, McCarthy, Catherine, Luna, Paula, Larralde, Margarita, Humphrey, Stephen, Holland, Kristen E., Hogeling, Marcia, Hidalgo-Matlock, Benjamin, Ferrari, Bruno, Fernandez-Faith, Esteban, Drolet, Beth, Cordoro, Kelly M., Bowcock, Anne M., Antaya, Richard J., Ashack, Kurt, Ashack, Richard J., Lifton, Richard P., Milstone, Leonard M., Paller, Amy S., Choate, Keith A., Craiglow, Brittany G., Boyden, Lynn M., Hu, Ronghua, Virtanen, Marie, Su, John, Rodriguez, Gabriela, McCarthy, Catherine, Luna, Paula, Larralde, Margarita, Humphrey, Stephen, Holland, Kristen E., Hogeling, Marcia, Hidalgo-Matlock, Benjamin, Ferrari, Bruno, Fernandez-Faith, Esteban, Drolet, Beth, Cordoro, Kelly M., Bowcock, Anne M., Antaya, Richard J., Ashack, Kurt, Ashack, Richard J., Lifton, Richard P., Milstone, Leonard M., Paller, Amy S., and Choate, Keith A.

Abstract

Background: Heterozygous mutations in caspase recruitment domain family member 14 gene (CARD14) have been shown to be associated with psoriasis and familial pityriasis rubra pilaris (PRP). Many subjects with CARD14 mutations display features of both disorders, which can result in diagnostic uncertainty. In addition, these eruptions are often recalcitrant to conventional psoriasis therapies such as methotrexate, oral retinoids, and tumor necrosis factor-alpha inhibitors. Objective: We sought to describe the clinical characteristics, family history, and response to therapy in subjects with papulosquamous eruptions due to mutations in CARD14. Methods: Subjects were referred for genetic testing as part of a registry of subjects with inherited disorders of keratinization. DNA was isolated from blood or saliva, and multiplex targeted sequencing or whole exome sequencing was performed. Clinical histories of subjects with CARD14 mutations were reviewed. Results: We identified 15 kindreds with CARD14-associated papulosquamous eruption (CAPE). Characteristic features of CAPE include early age of onset; prominent involvement of the cheeks, chin, and ears; family history of psoriasis or PRP; minimal response to conventional topical and systemic psoriasis therapies; and improvement with ustekinumab. Limitations: Relatively small sample size. Conclusions: Many subjects with CARD14 mutations display characteristics of both psoriasis and PRP. We propose the term CARD14-associated papulosquamous eruption to describe this spectrum of disease. Subjects with clinical features suggestive of CAPE should undergo CARD14 sequencing and may benefit from treatment with ustekinumab.

Published
2018
Full Text
View/download PDF

88. A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents.

Author

Bronckers, Inge M. G. J., Paller, Amy S., West, Dennis P., Lara-Corrales, Irene, Tollefson, Megha M., Tom, Wynnis L., Hogeling, Marcia, Belazarian, Leah, Zachariae, Claus, Mahé, Emmanuel, Siegfried, Elaine, Blume-Peytavi, Ulrike, Szalai, Zsuzsanna, Vleugels, Ruth Ann, Holland, Kristen, Murphy, Ruth, Puig, Lluís, Cordoro, Kelly M., Lambert, Jo, and Alexopoulos, Alex

Published
2020
Full Text
View/download PDF

89. Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation

Author

Ford, Adam R., primary, Siegel, Michael, additional, Bagel, Jerry, additional, Cordoro, Kelly M., additional, Garg, Amit, additional, Gottlieb, Alice, additional, Green, Lawrence J., additional, Gudjonsson, Johann E., additional, Koo, John, additional, Lebwohl, Mark, additional, Liao, Wilson, additional, Mandelin, Arthur M., additional, Markenson, Joseph A., additional, Mehta, Nehal, additional, Merola, Joseph F., additional, Prussick, Ronald, additional, Ryan, Caitriona, additional, Schwartzman, Sergio, additional, Siegel, Evan L., additional, Van Voorhees, Abby S., additional, Wu, Jashin J., additional, and Armstrong, April W., additional

Published
2018
Full Text
View/download PDF

92. Pediatric psoriasis: Evolving perspectives

Author

Eichenfield, Lawrence F., primary, Paller, Amy S., additional, Tom, Wynnis L., additional, Sugarman, Jeffrey, additional, Hebert, Adelaide A., additional, Friedlander, Sheila Fallon, additional, Siegfried, Elaine, additional, Silverberg, Nanette, additional, and Cordoro, Kelly M., additional

Published
2018
Full Text
View/download PDF

95. Concurrent Subcutaneous Panniculitis-like T-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia in 2 Pediatric Patients

Author

Smith, Geoffrey A., Levinson, Anya L., Galvin, Robert T., Lalor, Leah E., McCalmont, Timothy, Wang, Linlin, Geis, Michael C., Odegaard, Karah, Hupp, Meghan, Maguiness, Sheilagh, Turcotte, Lucie M., Cordoro, Kelly M., and Hermiston, Michelle L.

Abstract

Subcutaneous panniculitis-like T-cell lymphoma is a cutaneous lymphoma characterized by CD8+T-cell infiltrate in the subcutis that is rare in children. Acute lymphoblastic lymphoma is the most common pediatric malignancy and often presents with fevers and pancytopenia. Herein, we report 2 pediatric patients presenting with subcutaneous panniculitis-like T-cell lymphoma and B-cell acute lymphoblastic lymphoma, distinct hematologic malignancies arising from different lymphoid lineages, with no identifiable germline cancer predisposition.

Published
2024
Full Text
View/download PDF

96. Guidelines of Care for the Management of Atopic Dermatitis Part 4: Prevention of Disease Flares and Use of Adjunctive Therapies and Approaches

Author

Sidbury, Robert, Tom, Wynnis L., Bergman, James N., Cooper, Kevin D., Silverman, Robert A., Berger, Timothy G., Chamlin, Sarah L., Cohen, David E., Cordoro, Kelly M., Davis, Dawn M., Feldman, Steven R., Hanifin, Jon M., Krol, Alfons, Margolis, David J., Paller, Amy S., Schwarzenberger, Kathryn, Simpson, Eric L., Williams, Hywel C., Elmets, Craig A., Block, Julie, Harrod, Christopher G., Begolka, Wendy Smith, and Eichenfield, Lawrence F.

Subjects
Evidence-Based Medicine, Practice Guidelines as Topic, Hypersensitivity, Humans, Dermatologic Agents, Article, Immunosuppressive Agents, Dermatitis, Atopic
Abstract

Atopic dermatitis (AD) is a common, chronic inflammatory dermatosis that can affect all age groups. This evidence-based guideline addresses important clinical questions that arise in its management. In this final section, treatments for flare prevention and adjunctive and complementary therapies and approaches are reviewed. Suggestions on utilization are given based on available evidence.

Published
2014

97. GUIDELINES OF CARE FOR THE MANAGEMENT OF ATOPIC DERMATITIS: Part 3: Management and Treatment with Phototherapy and Systemic Agents

Author

Sidbury, Robert, Davis, Dawn M., Cohen, David E., Cordoro, Kelly M., Berger, Timothy G., Bergman, James N., Chamlin, Sarah L., Cooper, Kevin D., Feldman, Steven R., Hanifin, Jon M., Krol, Alfons, Margolis, David J., Paller, Amy S., Schwarzenberger, Kathryn, Silverman, Robert A., Simpson, Eric L., Tom, Wynnis L., Williams, Hywel C., Elmets, Craig A., Block, Julie, Harrod, Christopher G., Begolka, Wendy Smith, and Eichenfield, Lawrence F.

Subjects
Interferon-gamma, Methotrexate, Anti-Infective Agents, Azathioprine, Cyclosporine, Histamine Antagonists, Humans, Immunologic Factors, Mycophenolic Acid, Phototherapy, Article, Dermatitis, Atopic
Abstract

Atopic dermatitis is a chronic, pruritic inflammatory dermatosis that affects up to 25% of children and 2% to 3% of adults. This guideline addresses important clinical questions that arise in atopic dermatitis management and care, providing recommendations based on the available evidence. In this third of 4 sections, treatment of atopic dermatitis with phototherapy and systemic immunomodulators, antimicrobials, and antihistamines is reviewed, including indications for use and the risk-benefit profile of each treatment option.

Published
2014

99. GUIDELINES OF CARE FOR THE MANAGEMENT OF ATOPIC DERMATITIS: Part 1: Diagnosis and Assessment of Atopic Dermatitis

Author

Eichenfield, Lawrence F., Tom, Wynnis L., Chamlin, Sarah L., Feldman, Steven R., Hanifin, Jon M., Simpson, Eric L., Berger, Timothy G., Bergman, James N., Cohen, David E., Cooper, Kevin D., Cordoro, Kelly M., Davis, Dawn M., Krol, Alfons, Margolis, David J., Paller, Amy S., Schwarzenberger, Kathryn, Silverman, Robert A., Williams, Hywel C., Elmets, Craig A., Block, Julie, Harrod, Christopher G., Begolka, Wendy Smith, and Sidbury, Robert

Subjects
Adult, Male, Evidence-Based Medicine, Adolescent, Age Factors, Comorbidity, Filaggrin Proteins, Prognosis, Risk Assessment, Severity of Illness Index, Article, Dermatitis, Atopic, Young Adult, Chronic Disease, Practice Guidelines as Topic, Quality of Life, Humans, Female, Child, Physical Examination, Biomarkers
Abstract

Atopic dermatitis (AD) is a chronic, pruritic, inflammatory dermatosis that affects up to 25% of children and 2% to 3% of adults. This guideline addresses important clinical questions that arise in the management and care of AD, providing updated and expanded recommendations based on the available evidence. In this first of 4 sections, methods for the diagnosis and monitoring of disease, outcomes measures for assessment, and common clinical associations that affect patients with AD are discussed. Known risk factors for the development of disease are also reviewed.

Published
2013

100. Atypical Cases of Scleroderma en Coup de Sabre

Author

Kraus, Verena, primary, Lawson, Erica F., additional, Scheven, Emily von, additional, Tihan, Tarik, additional, Garza, Judith, additional, Nathan, Rani G., additional, Cordoro, Kelly M., additional, and Waubant, Emmanuelle, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results